Retour
Prix Anthera Pharmaceuticals Inc (ANTH)
Graphique du cours de l'action ANTH
ANTH Gagner
Anthera Pharmaceuticals Inc
$0
0%
$0
À la fermeture : Feb 13, 16:00:00 GMT-5
$0
0%
$0
Post-Marché: Feb 13, 20:00:00 GMT-5
Pas encore de donnéesEarnings FAQ
Comment le bénéfice par action récent de ANTH se compare-t-il aux attentes ?
Comment les revenus de Anthera Pharmaceuticals Inc ANTH se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Anthera Pharmaceuticals Inc ?
Quel est le score de qualité des bénéfices pour Anthera Pharmaceuticals Inc ?
Quand Anthera Pharmaceuticals Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Anthera Pharmaceuticals Inc ?
Anthera Pharmaceuticals Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.0001
Prix d'ouverture
$0
Plage de la journée
$0 - $0
Plage de 52 semaines
$0 - $0.001
Volume
23.8K
Volume moyen
5.4K
BPA (TTM)
-1.63
Rendement en dividend
--
Capitalisation boursière
$2.6K
Qu’est-ce que ANTH ?
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.